SMH
·general
·1 hour ago
WA biotech duo takes aim at diabetes beyond Ozempic
Western Australian biotech firm ProGenis Pharmaceuticals, backed by Perth-based Syngenis Labs, is developing RNA therapies targeting insulin resistance in type 2 diabetes where GLP-1 drugs like Ozempic fall short. The antisense oligonucleotide platform acts at the molecular level to improve insulin signaling, addressing underlying disease drivers rather than just metabolic symptoms.
Summary by Glance · SMH
Newer
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI